Clinical Staphylococcus aureus inhibits human T-cell activity through interaction with the PD-1 receptor

mBio. 2023 Oct 31;14(5):e0134923. doi: 10.1128/mbio.01349-23. Epub 2023 Oct 5.

Abstract

Therapies that target and aid the host immune defense to repel cancer cells or invading pathogens are rapidly emerging. Antibiotic resistance is among the largest threats to human health globally. Staphylococcus aureus (S. aureus) is the most common bacterial infection, and it poses a challenge to the healthcare system due to its significant ability to develop resistance toward current available therapies. In long-term infections, S. aureus further adapt to avoid clearance by the host immune defense. In this study, we discover a new interaction that allows S. aureus to avoid elimination by the immune system, which likely supports its persistence in the host. Moreover, we find that blocking the specific receptor (PD-1) using antibodies significantly relieves the S. aureus-imposed inhibition. Our findings suggest that therapeutically targeting PD-1 is a possible future strategy for treating certain antibiotic-resistant staphylococcal infections.

Keywords: ClpP mutation; T cells; adaptive immunity; clinical Staphylococcus aureus; immune evasion.

MeSH terms

  • Humans
  • Methicillin-Resistant Staphylococcus aureus*
  • Programmed Cell Death 1 Receptor
  • Staphylococcal Infections* / microbiology
  • Staphylococcus aureus
  • T-Lymphocytes

Substances

  • Programmed Cell Death 1 Receptor